Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
The presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, response to checkpoint-inhibitors and antigen-specific active immunotherapy is limited in ovarian cancer. The goal of...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01273/full |
| _version_ | 1819209314997370880 |
|---|---|
| author | Thaïs Baert Thaïs Baert Ann Vankerckhoven Matteo Riva Anaïs Van Hoylandt Gitte Thirion Gerhardt Holger Thomas Mathivet Thomas Mathivet Ignace Vergote Ignace Vergote Ignace Vergote An Coosemans An Coosemans |
| author_facet | Thaïs Baert Thaïs Baert Ann Vankerckhoven Matteo Riva Anaïs Van Hoylandt Gitte Thirion Gerhardt Holger Thomas Mathivet Thomas Mathivet Ignace Vergote Ignace Vergote Ignace Vergote An Coosemans An Coosemans |
| author_sort | Thaïs Baert |
| collection | DOAJ |
| description | The presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, response to checkpoint-inhibitors and antigen-specific active immunotherapy is limited in ovarian cancer. The goal of our study was to investigate the interaction between ovarian cancer and the innate and adaptive immune system in the ID8-fLuc syngeneic ovarian cancer mouse model. For the in vivo experiments C57BL/6, B6.129S7-Rag1tm1Mom/J, and B6.129P2(SJL)-Myd88tm1.1Defr/J mice were inoculated with ID8-fLuc. In vivo depletion experiments were performed using clodronate liposomes (CL), anti-CD8a, anti-GR1, anti-colony stimulating factor 1 (anti-CSF1), and TMβ1 (anti-CD122). Immune read out was performed by fluorescent activated cell sorting analysis for effector T cells, regulatory T cells, natural killer cells, B cells, macrophages, and myeloid derived suppressor cells (MDSC), immunohistochemistry for MDSC and tumor-associated macrophages (TAM) and immunofluorescence for M1 and M2 TAM in the vascular context. The effect of MDSC on T cell proliferation and phenotype were studied in vitro. We discovered that the absence of T and B cells did not influence tumor growth or survival of B6.129S7-Rag1tm1Mom/J mice compared to immunocompetent C57BL/6 mice. CL-induced macrophage depletion promoted tumor proliferation and shortened survival in C57BL/6 mice (p = 0.004) and in B6.129S7-Rag1tm1Mom/J mice (p = 0.0005). During CL treatment, we observed a clear increase of pro-inflammatory cytokines (p ≤ 0.02) and monocytic MDSC (p ≤ 0.01). Selective depletion of MDSC by anti-GR1 improved survival, certainly in comparison to mice treated with anti-CSF1 (p = 0.01—median survival 91 vs. 67.5 days). B6.129P2(SJL)-Myd88tm1.1Defr/J mice displayed to a longer median survival compared to C57BL/6 mice (90 vs. 76 days). MDSC activated by ID8-fLuc conditioned medium or ascites of tumor-bearing mice showed T cell suppressive functions in vitro. Based on these findings, we conclude that the adaptive immune system does not efficiently control tumor growth in the ID8-fLuc model. In addition, we discovered a prominent role for MDSC as the driver of immunosuppression in the ID8-fLuc ovarian cancer mouse model. |
| first_indexed | 2024-12-23T05:53:19Z |
| format | Article |
| id | doaj.art-a884f2f1798146ddb9bdf3bf6b81fc6d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-23T05:53:19Z |
| publishDate | 2019-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a884f2f1798146ddb9bdf3bf6b81fc6d2022-12-21T17:57:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-06-011010.3389/fimmu.2019.01273458116Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian CancerThaïs Baert0Thaïs Baert1Ann Vankerckhoven2Matteo Riva3Anaïs Van Hoylandt4Gitte Thirion5Gerhardt Holger6Thomas Mathivet7Thomas Mathivet8Ignace Vergote9Ignace Vergote10Ignace Vergote11An Coosemans12An Coosemans13ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, GermanyImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumLaboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumVascular Patterning Lab, Center for Cancer Biology, VIB, KU Leuven, Leuven, BelgiumVascular Patterning Lab, Center for Cancer Biology, VIB, KU Leuven, Leuven, BelgiumPARCC, HEGP Institute (team 9), INSERM U970, Université Paris Descartes, Paris, FranceImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumLaboratory of Gynecologic Oncology, Department of Oncology, KU Leuven, Leuven, BelgiumDepartment of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven (UZ Leuven), Leuven, BelgiumImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, BelgiumDepartment of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven (UZ Leuven), Leuven, BelgiumThe presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, response to checkpoint-inhibitors and antigen-specific active immunotherapy is limited in ovarian cancer. The goal of our study was to investigate the interaction between ovarian cancer and the innate and adaptive immune system in the ID8-fLuc syngeneic ovarian cancer mouse model. For the in vivo experiments C57BL/6, B6.129S7-Rag1tm1Mom/J, and B6.129P2(SJL)-Myd88tm1.1Defr/J mice were inoculated with ID8-fLuc. In vivo depletion experiments were performed using clodronate liposomes (CL), anti-CD8a, anti-GR1, anti-colony stimulating factor 1 (anti-CSF1), and TMβ1 (anti-CD122). Immune read out was performed by fluorescent activated cell sorting analysis for effector T cells, regulatory T cells, natural killer cells, B cells, macrophages, and myeloid derived suppressor cells (MDSC), immunohistochemistry for MDSC and tumor-associated macrophages (TAM) and immunofluorescence for M1 and M2 TAM in the vascular context. The effect of MDSC on T cell proliferation and phenotype were studied in vitro. We discovered that the absence of T and B cells did not influence tumor growth or survival of B6.129S7-Rag1tm1Mom/J mice compared to immunocompetent C57BL/6 mice. CL-induced macrophage depletion promoted tumor proliferation and shortened survival in C57BL/6 mice (p = 0.004) and in B6.129S7-Rag1tm1Mom/J mice (p = 0.0005). During CL treatment, we observed a clear increase of pro-inflammatory cytokines (p ≤ 0.02) and monocytic MDSC (p ≤ 0.01). Selective depletion of MDSC by anti-GR1 improved survival, certainly in comparison to mice treated with anti-CSF1 (p = 0.01—median survival 91 vs. 67.5 days). B6.129P2(SJL)-Myd88tm1.1Defr/J mice displayed to a longer median survival compared to C57BL/6 mice (90 vs. 76 days). MDSC activated by ID8-fLuc conditioned medium or ascites of tumor-bearing mice showed T cell suppressive functions in vitro. Based on these findings, we conclude that the adaptive immune system does not efficiently control tumor growth in the ID8-fLuc model. In addition, we discovered a prominent role for MDSC as the driver of immunosuppression in the ID8-fLuc ovarian cancer mouse model.https://www.frontiersin.org/article/10.3389/fimmu.2019.01273/fullovarian cancerimmunosuppressionmyeloid derived suppressor cellsadaptive immune systeminnate immune system |
| spellingShingle | Thaïs Baert Thaïs Baert Ann Vankerckhoven Matteo Riva Anaïs Van Hoylandt Gitte Thirion Gerhardt Holger Thomas Mathivet Thomas Mathivet Ignace Vergote Ignace Vergote Ignace Vergote An Coosemans An Coosemans Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer Frontiers in Immunology ovarian cancer immunosuppression myeloid derived suppressor cells adaptive immune system innate immune system |
| title | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
| title_full | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
| title_fullStr | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
| title_full_unstemmed | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
| title_short | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
| title_sort | myeloid derived suppressor cells key drivers of immunosuppression in ovarian cancer |
| topic | ovarian cancer immunosuppression myeloid derived suppressor cells adaptive immune system innate immune system |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2019.01273/full |
| work_keys_str_mv | AT thaisbaert myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT thaisbaert myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT annvankerckhoven myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT matteoriva myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT anaisvanhoylandt myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT gittethirion myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT gerhardtholger myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT thomasmathivet myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT thomasmathivet myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT ignacevergote myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT ignacevergote myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT ignacevergote myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT ancoosemans myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT ancoosemans myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer |